IMMUNIC, INC. Form 8-K Summary
Business Context and Reporting Period
This Current Report on Form 8-K was filed by Immunic, Inc. (IMUX) on April 14, 2026. The report details the results of a Special Meeting of Stockholders held on the same date and the subsequent Board approval of a reverse stock split.
Key Financial Metrics
The filing text does not provide specific values for revenue, profit, cash flow, margins, debt, or liquidity. This report focuses exclusively on corporate governance actions and capital structure changes.
Material Changes and Voting Results
Stockholders voted on a proposal to authorize the Board to effect a reverse stock split. The voting results were as follows:
- Shares Outstanding: 130,464,825
- Shares Present/Represented: 70,622,667 (approximately 54.1%)
- Votes For: 57,404,749
- Votes Against: 12,594,555
- Abstentions: 623,363
Following the vote, the Board approved a specific reverse stock split ratio of 1-for-10.
Outlook, Risks, and Implementation Details
The reverse stock split is expected to become effective at 12:01 a.m. Eastern Time on April 27, 2026. Post-split shares ("New Common Stock") are expected to begin trading on the Nasdaq Capital Market on April 27, 2026, under the existing symbol "IMUX." The new CUSIP identifier will be 4525EP200. The filing includes standard forward-looking statement disclaimers regarding market conditions, cash needs, and general business risks.
Investor Verification Checklist
- Verify the effective date and time of the 1-for-10 reverse stock split (April 27, 2026).
- Confirm the new CUSIP number (4525EP200) for post-split trading.
- Review the Definitive Proxy Statement filed on March 2, 2026, for detailed rationale behind the split.
- Monitor Nasdaq Capital Market trading status for IMUX on April 27, 2026.